A pooled retrospective analysis reported that fluorine-18 DCFPyL PET/CT detected recurrent prostate cancer in a substantial fraction of patients even at ultra-low PSA levels. The results showed detection rates of 33% for ultra-low PSA and 49% for low PSA, suggesting clinical utility earlier than conventional salvage testing thresholds. The advance matters for prostate oncology pathways because lower PSA recurrence detection can impact treatment timing and decision-making for imaging-driven management. It also informs patient selection for PET-based surveillance and restaging. While retrospective and pooled, the data provide a signal that DCFPyL is sensitive enough to identify recurrence without waiting for higher PSA rises. The provided item did not include performance metrics such as specificity, nor did it detail impact on downstream outcomes, which will be key for prospective validation.